Agios Pharmaceuticals | AGIO - Assets


Agios Pharmaceuticals reported $1.39B in Assets for its fiscal quarter ending in September of 2025.





Assets Change Date
AbbVie USD 133.9B 3.28B Sep/2025
Agios Pharmaceuticals USD 1.39B 85.53M Sep/2025
Alnylam Pharmaceuticals USD 4.85B 285.64M Sep/2025
Amgen USD 90.14B 2.24B Sep/2025
Arrowhead Research USD 1.39B 4.68M Sep/2025
Astellas Pharma JPY 3.45T 114.46B Sep/2025
AstraZeneca USD 114.46B 2.03B Sep/2025
Bayer EUR 104.21B 1.03B Sep/2025
Biogen USD 29.21B 877.3M Sep/2025
BioMarin Pharmaceutical USD 7.61B 158.53M Sep/2025
Bristol-Myers Squibb USD 96.89B 2.21B Sep/2025
Daiichi Sankyo JPY 3.82T 252.52B Dec/2025
Eli Lilly USD 114.94B 14.01B Sep/2025
Exelixis USD 2.82B 145.47M Sep/2025
Gilead Sciences USD 58.53B 2.81B Sep/2025
GlaxoSmithKline GBP 61.34B 2.08B Sep/2025
Incyte USD 6.33B 509M Sep/2025
Ionis Pharmaceuticals USD 3.03B 47.96M Sep/2025
Merck USD 129.55B 12.02B Sep/2025
Moderna USD 12.14B 125M Sep/2025
Novartis USD 107.29B 2.89B Sep/2025
Novartis USD 107.29B 2.89B Sep/2025
Pfizer USD 208.73B 2.64B Sep/2025
Regeneron Pharmaceuticals USD 40.56B 389.3M Dec/2025
Roche Holding CHF 100.7B 5.94B Dec/2025
Sarepta Therapeutics USD 3.49B 186.38M Sep/2025
Vertex Pharmaceuticals USD 24.86B 825.6M Sep/2025